Cryoport Continues to Freeze Competition with Strong Q2 2026 Earnings
Cryoport Inc., a leading global provider of temperature-controlled supply chain solutions, continued its remarkable growth trajectory in the second quarter of 2026. According to the company's recent earnings conference call transcript, Cryoport's revenue momentum, which has been building over several periods, accelerated during Q2 with total revenue reaching $49 million.
The Life Sciences Services segment was the primary driver of this growth, with a 15% year-over-year increase in revenue. This was largely due to a 25% surge in BioStorage BioServices revenue. The support for commercial cell and gene therapy also saw significant growth, with services portion revenue increasing by 26% compared to Q2 2025.
The company's strong performance was underscored by Gerry, Chief Executive Officer of Cryoport, who stated during the conference call that "our growth reflects the value of Cryoport's integrated end-to-end platform across the life sciences ecosystem as well as the growing adoption of cell and gene therapies."
One notable highlight from Q2 2026 was the FDA approval received by Orca Bio for TREGZI. This led to an increase in the number of commercial cell and gene therapies supported by Cryoport, which now stands at 22. The company's total clinical trial count also reached 779 globally, a net increase of 51 trials over the prior year.
Cryoport's commanding position in the market was further emphasized by its support for approximately 70% of the cell and gene therapy industry's clinical trials. Based on current information, the company expects to see another 11 possible BLA/MAA application filings, five additional new therapy approvals, and one additional approval for a label and/or geographic expansion for the balance of 2026.
The Life Sciences Products business also generated solid results during Q2, demonstrating Cryoport's continued commitment to delivering innovative solutions across the life sciences ecosystem. As Cryoport continues to build on its momentum, investors and industry stakeholders will be closely watching the company's progress in the coming quarters.
